Haleon plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLNCF research report →
Companywww.haleon.com
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum.
- CEO
- Brian James McNamara
- IPO
- 2022
- Employees
- 24,561
- HQ
- Weybridge, GB
Price Chart
Valuation
- Market Cap
- $39.10B
- P/E
- 29.80
- P/S
- 3.67
- P/B
- 1.88
- EV/EBITDA
- 18.10
- Div Yield
- 2.08%
Profitability
- Gross Margin
- 61.45%
- Op Margin
- 18.85%
- Net Margin
- 12.59%
- ROE
- 6.43%
- ROIC
- 4.13%
Growth & Income
- Revenue
- $11.03B · -1.82%
- Net Income
- $1.67B · 15.58%
- EPS
- $0.19 · 18.75%
- Op Income
- $2.47B
- FCF YoY
- 1.60%
Performance & Tape
- 52W High
- $5.80
- 52W Low
- $4.25
- 50D MA
- $4.81
- 200D MA
- $4.87
- Beta
- 0.25
- Avg Volume
- 10.91K
Get TickerSpark's AI analysis on HLNCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HLNCF Coverage
We haven't published any research on HLNCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HLNCF Report →